<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="description" content="bis620.final">
<title>Project Abstract • bis620.final</title>
<script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Project Abstract">
<meta property="og:description" content="bis620.final">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">bis620.final</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.1.0</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="active nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/abstract.html">Project Abstract</a>
  </div>
</li>
      </ul>
<form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off">
</form>

      <ul class="navbar-nav"></ul>
</div>

    
  </div>
</nav><div class="container template-article">




<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>Project Abstract</h1>
                        <h4 data-toc-skip class="author">Yining Chen,
Yufei Deng, Ziqing Ji</h4>
            
            <h4 data-toc-skip class="date">2023-12-20</h4>
      
      
      <div class="d-none name"><code>abstract.Rmd</code></div>
    </div>

    
    
<div class="section level2">
<h2 id="background-and-motivation">Background and Motivation<a class="anchor" aria-label="anchor" href="#background-and-motivation"></a>
</h2>
<p>Colorectal cancer (CRC) is the third most common cancer type and the
second leading cause of all cancer deaths, representing about 10% of all
cancer diagnoses worldwide. In the United States, there are more than
one million people living with CRC, and 4.2% percent of all adults are
expected to be diagnosed with CRC at some point in their lives. CRC is
also highly metastatic–more than 50% of the patients with CRC are
expected to experience metastases during the course of their
disease. </p>
<p>In recent decades, we have seen many advancements in the treatment of
metastatic CRC (mCRC), including developments of traditional surgical
and/or chemotherapy procedures (e.g. FOLFOX), new targeted therapies
tailored for individual genetic and molecular profiles (e.g.,
Panitumumab, Aflibercept, etc.), as well as the emergence of new
immunotherapeutic drugs (e.g., Pembrolizumab, Nivolumab, and
Ipilimumab). Knowing the past trends in these clinical developments can
provide valuable insights into the future directions of mCRC
treatment.</p>
<p>Therefore, utilizing the openly accessible database from <a href="https://clinicaltrials.gov/" class="external-link">ClinicalTrials.gov</a>, our project
aims to explore and summarize some of the key underlying trends and
characteristics in recent clinical trials on mCRC, including 1) the
evolution of the distribution of intervention categories (e.g., drug,
device, behavioral, etc.) over time, 2) the number of different
therapeutic approaches being investigated over time, and 3) factors
impacting trial completion and success (e.g., study type, phase,
sponsorship, etc.). Addressing these questions will help obtain a
clearer picture of the current landscape of clinical research on the
condition of mCRC, potentially showing us future prospects toward
expanded treatment options and enhanced precision medicines for
mCRC.</p>
</div>
<div class="section level2">
<h2 id="research-question">Research Question<a class="anchor" aria-label="anchor" href="#research-question"></a>
</h2>
<ul>
<li>Which factor(s) shows a significant influence on enrollment numbers
in mCRC clinical trials?</li>
<li>Prediction: How do the phase of the trial, enrollment numbers, and
source class collectively influence the study duration of mCRC clinical
trials?</li>
<li>Classification: How can we predict the overall completion status
using a set of factors, including enrollment, study duration, phase,
intervention type, and source class?</li>
</ul>
</div>
<div class="section level2">
<h2 id="data-cleaning-and-exploration">Data Cleaning and Exploration<a class="anchor" aria-label="anchor" href="#data-cleaning-and-exploration"></a>
</h2>
<div class="section level3">
<h3 id="datasets-used-in-analysis">Datasets Used in Analysis<a class="anchor" aria-label="anchor" href="#datasets-used-in-analysis"></a>
</h3>
<p>We first extract the <code>nct_ids</code> of clinical trials for
metastatic colorectal cancer from the clinicaltrials.gov database using
the dplyr <code>filter</code> query. Then, the nct_ids are used to join
datasets with study information and intervention types and descriptions.
This allows us to derive the two datasets that we will use for the
analyses:</p>
<ul>
<li>
<p>The <code>crc</code> data table contains information about
individual mCRC clinical trials, with each entry representing one trial.
There are 717 entries and 12 variables. Variables include study id,
title, start date, completion date, phase, etc.</p>
<div class="sourceCode" id="cb1"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="https://zqji0610.github.io/bis620.final/" class="external-link">bis620.final</a></span><span class="op">)</span></span>
<span><span class="va">crc</span> <span class="op">|&gt;</span> <span class="fu"><a href="https://rdrr.io/r/utils/head.html" class="external-link">head</a></span><span class="op">(</span><span class="fl">5</span><span class="op">)</span></span>
<span><span class="co">#&gt; <span style="color: #949494;"># A tibble: 5 × 12</span></span></span>
<span><span class="co">#&gt;   nct_id      condition_name   start_date completion_date study_type brief_title</span></span>
<span><span class="co">#&gt;   <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>       <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>            <span style="color: #949494; font-style: italic;">&lt;date&gt;</span>     <span style="color: #949494; font-style: italic;">&lt;date&gt;</span>          <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>      <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>      </span></span>
<span><span class="co">#&gt; <span style="color: #BCBCBC;">1</span> NCT01531595 Metastatic Colo… 2012-02-29 2025-12-31      Intervent… Study of B…</span></span>
<span><span class="co">#&gt; <span style="color: #BCBCBC;">2</span> NCT01531621 Metastatic Colo… 2012-02-29 2025-12-31      Observati… A Populati…</span></span>
<span><span class="co">#&gt; <span style="color: #BCBCBC;">3</span> NCT01532804 Metastatic Colo… 2011-07-28 2019-01-31      Intervent… 2nd-line T…</span></span>
<span><span class="co">#&gt; <span style="color: #BCBCBC;">4</span> NCT01533740 Metastatic Colo… 2012-03-31 2014-02-28      Observati… Circulatin…</span></span>
<span><span class="co">#&gt; <span style="color: #BCBCBC;">5</span> NCT01539824 Metastatic Colo… 2012-02-29 2014-08-31      Intervent… A Study of…</span></span>
<span><span class="co">#&gt; <span style="color: #949494;"># ℹ 6 more variables: official_title &lt;chr&gt;, overall_status &lt;chr&gt;, phase &lt;chr&gt;,</span></span></span>
<span><span class="co">#&gt; <span style="color: #949494;">#   enrollment &lt;dbl&gt;, why_stopped &lt;chr&gt;, source_class &lt;chr&gt;</span></span></span></code></pre></div>
</li>
<li>
<p>The <code>crc_sub</code> data table merged additional information
about intervention groups (arms) to the <code>crc</code> data table,
with one clinical trial potentially having multiple groups. There are
1,697 entries and 16 variables.</p>
<div class="sourceCode" id="cb2"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="va">crc_sub</span> <span class="op">|&gt;</span> <span class="fu"><a href="https://rdrr.io/r/utils/head.html" class="external-link">head</a></span><span class="op">(</span><span class="fl">5</span><span class="op">)</span></span>
<span><span class="co">#&gt; <span style="color: #949494;"># A tibble: 5 × 16</span></span></span>
<span><span class="co">#&gt;   nct_id      condition_name intervention_id intervention_type intervention_name</span></span>
<span><span class="co">#&gt;   <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>       <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>                    <span style="color: #949494; font-style: italic;">&lt;dbl&gt;</span> <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>             <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>            </span></span>
<span><span class="co">#&gt; <span style="color: #BCBCBC;">1</span> NCT01531595 Metastatic Co…        60<span style="text-decoration: underline;">057</span>945 Drug              Bevacizumab plus…</span></span>
<span><span class="co">#&gt; <span style="color: #BCBCBC;">2</span> NCT01531621 Metastatic Co…        60<span style="text-decoration: underline;">057</span>946 Other             Biomarker sampli…</span></span>
<span><span class="co">#&gt; <span style="color: #BCBCBC;">3</span> NCT01532804 Metastatic Co…        60<span style="text-decoration: underline;">058</span>040 Drug              bevacizumab, oxa…</span></span>
<span><span class="co">#&gt; <span style="color: #BCBCBC;">4</span> NCT01532804 Metastatic Co…        60<span style="text-decoration: underline;">058</span>041 Drug              Bevacizumab, oxa…</span></span>
<span><span class="co">#&gt; <span style="color: #BCBCBC;">5</span> NCT01533740 Metastatic Co…        60<span style="text-decoration: underline;">058</span>119 Drug              fluorouracil/iri…</span></span>
<span><span class="co">#&gt; <span style="color: #949494;"># ℹ 11 more variables: description &lt;chr&gt;, start_date &lt;date&gt;,</span></span></span>
<span><span class="co">#&gt; <span style="color: #949494;">#   completion_date &lt;date&gt;, study_type &lt;chr&gt;, brief_title &lt;chr&gt;,</span></span></span>
<span><span class="co">#&gt; <span style="color: #949494;">#   official_title &lt;chr&gt;, overall_status &lt;chr&gt;, phase &lt;chr&gt;, enrollment &lt;dbl&gt;,</span></span></span>
<span><span class="co">#&gt; <span style="color: #949494;">#   why_stopped &lt;chr&gt;, source_class &lt;chr&gt;</span></span></span></code></pre></div>
</li>
</ul>
</div>
<div class="section level3">
<h3 id="data-visualization">Data Visualization<a class="anchor" aria-label="anchor" href="#data-visualization"></a>
</h3>
<div class="section level4">
<h4 id="eplorative-data-analysis">Eplorative Data Analysis<a class="anchor" aria-label="anchor" href="#eplorative-data-analysis"></a>
</h4>
<p>To understand the underlying characteristics of mCRC clinical trials,
we drew attention to the distribution of interventional and
observational study designs, specifically stratified by the types of
intervention and study phases. The table below shows that there is a
clear dominance of interventional (or experimental) over observational
studies, as well as a prominence of interventions involving drugs over
any other forms. This is not surprising as drugs encompass a wide range
of therapeutic approaches such as protein binding pathway-targeted
drugs, immune checkpoint targeted drugs, and chemotherapy drugs, which
are all prodominant treatment options. Finally, we see that most
clinical trials (interventional studies) are phase 2 studies, which is
defined as “conducted to evaluate the effectiveness of the drug for a
particular indication or indications … and to determine the common
short-term side effects and risks”.</p>
<div class="sourceCode" id="cb3"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="fu"><a href="../reference/summarize_crc_table.html">summarize_crc_table</a></span><span class="op">(</span><span class="op">)</span></span></code></pre></div>
<div id="koilpvsjkr" style="padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>#koilpvsjkr table {
  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';
  -webkit-font-smoothing: antialiased;
  -moz-osx-font-smoothing: grayscale;
}

#koilpvsjkr thead, #koilpvsjkr tbody, #koilpvsjkr tfoot, #koilpvsjkr tr, #koilpvsjkr td, #koilpvsjkr th {
  border-style: none;
}

#koilpvsjkr p {
  margin: 0;
  padding: 0;
}

#koilpvsjkr .gt_table {
  display: table;
  border-collapse: collapse;
  line-height: normal;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#koilpvsjkr .gt_caption {
  padding-top: 4px;
  padding-bottom: 4px;
}

#koilpvsjkr .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#koilpvsjkr .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 3px;
  padding-bottom: 5px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#koilpvsjkr .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#koilpvsjkr .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#koilpvsjkr .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#koilpvsjkr .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#koilpvsjkr .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#koilpvsjkr .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#koilpvsjkr .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#koilpvsjkr .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#koilpvsjkr .gt_spanner_row {
  border-bottom-style: hidden;
}

#koilpvsjkr .gt_group_heading {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  text-align: left;
}

#koilpvsjkr .gt_empty_group_heading {
  padding: 0.5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#koilpvsjkr .gt_from_md > :first-child {
  margin-top: 0;
}

#koilpvsjkr .gt_from_md > :last-child {
  margin-bottom: 0;
}

#koilpvsjkr .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#koilpvsjkr .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
}

#koilpvsjkr .gt_stub_row_group {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
  vertical-align: top;
}

#koilpvsjkr .gt_row_group_first td {
  border-top-width: 2px;
}

#koilpvsjkr .gt_row_group_first th {
  border-top-width: 2px;
}

#koilpvsjkr .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#koilpvsjkr .gt_first_summary_row {
  border-top-style: solid;
  border-top-color: #D3D3D3;
}

#koilpvsjkr .gt_first_summary_row.thick {
  border-top-width: 2px;
}

#koilpvsjkr .gt_last_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#koilpvsjkr .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#koilpvsjkr .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#koilpvsjkr .gt_last_grand_summary_row_top {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: double;
  border-bottom-width: 6px;
  border-bottom-color: #D3D3D3;
}

#koilpvsjkr .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#koilpvsjkr .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#koilpvsjkr .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#koilpvsjkr .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#koilpvsjkr .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#koilpvsjkr .gt_sourcenote {
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#koilpvsjkr .gt_left {
  text-align: left;
}

#koilpvsjkr .gt_center {
  text-align: center;
}

#koilpvsjkr .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#koilpvsjkr .gt_font_normal {
  font-weight: normal;
}

#koilpvsjkr .gt_font_bold {
  font-weight: bold;
}

#koilpvsjkr .gt_font_italic {
  font-style: italic;
}

#koilpvsjkr .gt_super {
  font-size: 65%;
}

#koilpvsjkr .gt_footnote_marks {
  font-size: 75%;
  vertical-align: 0.4em;
  position: initial;
}

#koilpvsjkr .gt_asterisk {
  font-size: 100%;
  vertical-align: 0;
}

#koilpvsjkr .gt_indent_1 {
  text-indent: 5px;
}

#koilpvsjkr .gt_indent_2 {
  text-indent: 10px;
}

#koilpvsjkr .gt_indent_3 {
  text-indent: 15px;
}

#koilpvsjkr .gt_indent_4 {
  text-indent: 20px;
}

#koilpvsjkr .gt_indent_5 {
  text-indent: 25px;
}
</style>
<table class="table gt_table" data-quarto-disable-processing="false" data-quarto-bootstrap="false">
<thead><tr class="gt_col_headings">
<th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1" scope="col" id="&lt;strong&gt;Characteristic&lt;/strong&gt;"><strong>Characteristic</strong></th>
      <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="1" colspan="1" scope="col" id='&lt;strong&gt;Interventional&lt;/strong&gt;, N = 1,595&lt;span class="gt_footnote_marks" style="white-space:nowrap;font-style:italic;font-weight:normal;"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;'>
<strong>Interventional</strong>, N = 1,595<span class="gt_footnote_marks" style="white-space:nowrap;font-style:italic;font-weight:normal;"><sup>1</sup></span>
</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="1" colspan="1" scope="col" id='&lt;strong&gt;Observational&lt;/strong&gt;, N = 100&lt;span class="gt_footnote_marks" style="white-space:nowrap;font-style:italic;font-weight:normal;"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;'>
<strong>Observational</strong>, N = 100<span class="gt_footnote_marks" style="white-space:nowrap;font-style:italic;font-weight:normal;"><sup>1</sup></span>
</th>
    </tr></thead>
<tbody class="gt_table_body">
<tr>
<td headers="label" class="gt_row gt_left">intervention_type</td>
<td headers="stat_1" class="gt_row gt_center"><br></td>
<td headers="stat_2" class="gt_row gt_center"><br></td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Biological</td>
<td headers="stat_1" class="gt_row gt_center">118 (7.4%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (0%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Combination Product</td>
<td headers="stat_1" class="gt_row gt_center">10 (0.6%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (0%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Device</td>
<td headers="stat_1" class="gt_row gt_center">28 (1.8%)</td>
<td headers="stat_2" class="gt_row gt_center">1 (1.0%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Diagnostic Test</td>
<td headers="stat_1" class="gt_row gt_center">6 (0.4%)</td>
<td headers="stat_2" class="gt_row gt_center">13 (13%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Drug</td>
<td headers="stat_1" class="gt_row gt_center">1,314 (82%)</td>
<td headers="stat_2" class="gt_row gt_center">42 (42%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Genetic</td>
<td headers="stat_1" class="gt_row gt_center">14 (0.9%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (0%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Other</td>
<td headers="stat_1" class="gt_row gt_center">54 (3.4%)</td>
<td headers="stat_2" class="gt_row gt_center">26 (26%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Procedure</td>
<td headers="stat_1" class="gt_row gt_center">29 (1.8%)</td>
<td headers="stat_2" class="gt_row gt_center">18 (18%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Radiation</td>
<td headers="stat_1" class="gt_row gt_center">22 (1.4%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (0%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">phase</td>
<td headers="stat_1" class="gt_row gt_center"><br></td>
<td headers="stat_2" class="gt_row gt_center"><br></td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Early Phase 1</td>
<td headers="stat_1" class="gt_row gt_center">3 (0.2%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (NA%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Not Applicable</td>
<td headers="stat_1" class="gt_row gt_center">88 (5.5%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (NA%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Phase 1</td>
<td headers="stat_1" class="gt_row gt_center">196 (12%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (NA%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Phase 1/Phase 2</td>
<td headers="stat_1" class="gt_row gt_center">232 (15%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (NA%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Phase 2</td>
<td headers="stat_1" class="gt_row gt_center">809 (51%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (NA%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Phase 2/Phase 3</td>
<td headers="stat_1" class="gt_row gt_center">27 (1.7%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (NA%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Phase 3</td>
<td headers="stat_1" class="gt_row gt_center">226 (14%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (NA%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Phase 4</td>
<td headers="stat_1" class="gt_row gt_center">14 (0.9%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (NA%)</td>
</tr>
<tr>
<td headers="label" class="gt_row gt_left">    Unknown</td>
<td headers="stat_1" class="gt_row gt_center">0</td>
<td headers="stat_2" class="gt_row gt_center">100</td>
</tr>
</tbody>
<tfoot class="gt_footnotes"><tr>
<td class="gt_footnote" colspan="3">
<span class="gt_footnote_marks" style="white-space:nowrap;font-style:italic;font-weight:normal;"><sup>1</sup></span> n (%)</td>
    </tr></tfoot>
</table>
</div>
<p>Showing below is the Sankey diagram demonstrating the same
information as in the above table. Yet we included the graph to show
more straightforwardly the proportionality of the distributions.</p>
<div class="sourceCode" id="cb4"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="https://dplyr.tidyverse.org" class="external-link">dplyr</a></span><span class="op">)</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; Attaching package: 'dplyr'</span></span>
<span><span class="co">#&gt; The following objects are masked from 'package:stats':</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt;     filter, lag</span></span>
<span><span class="co">#&gt; The following objects are masked from 'package:base':</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt;     intersect, setdiff, setequal, union</span></span>
<span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="http://corybrunson.github.io/ggalluvial/" class="external-link">ggalluvial</a></span><span class="op">)</span></span>
<span><span class="co">#&gt; Loading required package: ggplot2</span></span>
<span><span class="fu"><a href="../reference/plot_crc_sankey.html">plot_crc_sankey</a></span><span class="op">(</span><span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">'2000-01-01'</span>,<span class="st">'2024-12-31'</span><span class="op">)</span><span class="op">)</span></span></code></pre></div>
<p><img src="abstract_files/figure-html/unnamed-chunk-5-1.png" width="700"></p>
</div>
<div class="section level4">
<h4 id="visualization-evolution-over-time">Visualization: Evolution Over Time<a class="anchor" aria-label="anchor" href="#visualization-evolution-over-time"></a>
</h4>
<p>A key question to the data is the evolving trend of clinical trials
over time. We therefore wanted to visualize the changes of total number
of mCRC clinical trials from the 2000s to the 2020s. Below shows the
total number of each type of the interventions across time, from which
we can see that 1) there is a clear increase in the overall total number
of trials and 2) the proportions of other types of interventions than
drugs seem to also increase over time.</p>
<div class="sourceCode" id="cb5"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="fu"><a href="../reference/plot_intervention_count_time.html">plot_intervention_count_time</a></span><span class="op">(</span><span class="op">)</span></span></code></pre></div>
<p><img src="abstract_files/figure-html/unnamed-chunk-6-1.png" width="700"></p>
<p>To investigate whether the second observation is actually true, we
generate another plot showing the proportions of different intervention
types (as shown below). We may see that there is a slight increase in
the proportion of biological interventions over time, while the other
types (procedure, radiation, etc.) remain generally unchanged. This
might suggest that, being the traditional, gold-standard treatment,
radiological and surgical procedures are not actively research in
clinical trials; In contrast, new drugs representing various therapeutic
approaches are constantly being investigated in clinical studies.</p>
<div class="sourceCode" id="cb6"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="fu"><a href="../reference/plot_intervention_proportion_time.html">plot_intervention_proportion_time</a></span><span class="op">(</span><span class="op">)</span></span></code></pre></div>
<p><img src="abstract_files/figure-html/unnamed-chunk-7-1.png" width="700"></p>
<p>Lastly, to make specific inquiries into the temporal trends of the
clinical trials, we wrote a function that allows querying the data in
respect to specific therapies, intervention types, or any given keywords
and plotting the time trend accordingly. Bellow is an example of one of
the graphs showing the number of clinical trials with intervention type
“drug” over time.</p>
<div class="sourceCode" id="cb7"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="fu"><a href="../reference/plot_query_time_trend.html">plot_query_time_trend</a></span><span class="op">(</span><span class="st">"drug"</span>, <span class="fu"><a href="https://rlang.r-lib.org/reference/defusing-advanced.html" class="external-link">quo</a></span><span class="op">(</span><span class="va">intervention_type</span><span class="op">)</span><span class="op">)</span></span></code></pre></div>
<p><img src="abstract_files/figure-html/unnamed-chunk-8-1.png" width="700"></p>
</div>
</div>
</div>
<div class="section level2">
<h2 id="analysis">Analysis<a class="anchor" aria-label="anchor" href="#analysis"></a>
</h2>
<div class="section level3">
<h3 id="anova">Anova<a class="anchor" aria-label="anchor" href="#anova"></a>
</h3>
<p>We conducted statistical examinations to assess the variation in
enrollment numbers across 3 different factors: phase of the trial, the
duration of the study, and the source class.</p>
<div class="section level4">
<h4 id="enrollment-phase">1. Enrollment ~ Phase<a class="anchor" aria-label="anchor" href="#enrollment-phase"></a>
</h4>
<p>ANOVA to identify significant differences in enrollment among trial
phases, followed by Tukey’s Honest Significant Difference (HSD) test to
conduct pairwise comparisons between trial phases to identify where the
differences lay. Data is visualized using box plots, highlighting
enrollment distribution across phases. Outliers are indicated by red
asterisks, representing enrollments that are notably higher or lower
than the typical range for their respective phases.</p>
<div class="sourceCode" id="cb8"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="fu"><a href="../reference/enrollment_source_analysis.html">enrollment_source_analysis</a></span><span class="op">(</span><span class="op">)</span></span></code></pre></div>
<p><img src="abstract_files/figure-html/unnamed-chunk-9-1.png" width="700"></p>
<pre><code><span><span class="co">#&gt;                Df   Sum Sq Mean Sq F value Pr(&gt;F)    </span></span>
<span><span class="co">#&gt; source_class    4  5313780 1328445    23.5 &lt;2e-16 ***</span></span>
<span><span class="co">#&gt; Residuals    1692 95664266   56539                   </span></span>
<span><span class="co">#&gt; ---</span></span>
<span><span class="co">#&gt; Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt;  Kruskal-Wallis rank sum test</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; data:  enrollment by source_class</span></span>
<span><span class="co">#&gt; Kruskal-Wallis chi-squared = 103.3, df = 4, p-value &lt; 2.2e-16</span></span></code></pre>
<p><img src="abstract_files/figure-html/unnamed-chunk-9-2.png" width="700"></p>
</div>
<div class="section level4">
<h4 id="enrollment-source-class">2. Enrollment ~ Source Class<a class="anchor" aria-label="anchor" href="#enrollment-source-class"></a>
</h4>
<p>We performed the ANOVA and the Kruskal-Wallis test to determine if
there were significant differences in enrollment among various source
classes. To visualize enrollment distributions, we created a histogram
which provided an overview of enrollment frequencies, and a bar plot
that depicted mean enrollment counts by source class.</p>
<div class="sourceCode" id="cb10"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="fu"><a href="../reference/enrollment_phase_analysis.html">enrollment_phase_analysis</a></span><span class="op">(</span><span class="op">)</span></span>
<span><span class="co">#&gt;               Df   Sum Sq Mean Sq F value Pr(&gt;F)    </span></span>
<span><span class="co">#&gt; phase          7 32213310 4601901   203.4 &lt;2e-16 ***</span></span>
<span><span class="co">#&gt; Residuals   1589 35944031   22621                   </span></span>
<span><span class="co">#&gt; ---</span></span>
<span><span class="co">#&gt; Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1</span></span></code></pre></div>
<p><img src="abstract_files/figure-html/unnamed-chunk-10-1.png" width="700"><img src="abstract_files/figure-html/unnamed-chunk-10-2.png" width="700"></p>
</div>
<div class="section level4">
<h4 id="enrollment-study-duration">3. Enrollment ~ Study Duration<a class="anchor" aria-label="anchor" href="#enrollment-study-duration"></a>
</h4>
<p>Using ANOVA, we assessed the impact of study duration on enrollment
numbers. Additionally, we visualized this relationship through a scatter
plot created with ggplot2, which highlighted enrollment trends over the
duration of the studies. The data were filtered to include only trials
with complete enrollment and duration information, ensuring accuracy and
relevance in our analysis.</p>
<div class="sourceCode" id="cb11"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="fu"><a href="../reference/enrollment_duration_analysis.html">enrollment_duration_analysis</a></span><span class="op">(</span><span class="op">)</span></span>
<span><span class="co">#&gt;               Df   Sum Sq Mean Sq F value Pr(&gt;F)    </span></span>
<span><span class="co">#&gt; study_time     1  5943390 5943390   110.1 &lt;2e-16 ***</span></span>
<span><span class="co">#&gt; Residuals   1674 90388794   53996                   </span></span>
<span><span class="co">#&gt; ---</span></span>
<span><span class="co">#&gt; Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1</span></span></code></pre></div>
<p><img src="abstract_files/figure-html/unnamed-chunk-11-1.png" width="700"></p>
</div>
<div class="section level4">
<h4 id="regression-analysis">Regression Analysis:<a class="anchor" aria-label="anchor" href="#regression-analysis"></a>
</h4>
<p>A regression analysis was performed to fit and predict study duration
using several factors including enrollment, source class, and phase.Key
steps included filtering data for completeness, transforming dates, and
calculating study duration. A linear regression model was fitted, with
outlier removal guided by Cook’s distance with a threshold of 4/n. The
refined model’s results were evaluated through diagnostic plots and a
comparison of Actual vs. Predicted study durations plot.</p>
<div class="sourceCode" id="cb12"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="fu"><a href="../reference/duration_regression_analysis.html">duration_regression_analysis</a></span><span class="op">(</span><span class="op">)</span></span></code></pre></div>
<p><img src="images/regression1.png" style="width:70.0%"></p>
<p><img src="images/regression2.png" style="width:70.0%"></p>
<p><img src="images/regression3.png" style="width:60.0%"></p>
</div>
<div class="section level4">
<h4 id="overall-status-classification">Overall Status Classification<a class="anchor" aria-label="anchor" href="#overall-status-classification"></a>
</h4>
<p>In the classification task, we used a set of variables, including
duration, enrollment, intervention_type, source_class, and phase to
predict the overall status of a clinical trial through a logistic
regression model. Multiple combinations of variables were experimented
to optimize model performance. The target variable overall_status was
converted into a binary variable for this classification task.
Specifically, values of “Recruiting”, “Completed”, “Active, not
recruiting”, and “Not yet recruiting” are defined as class 1, and values
of “Terminated”, “Withdrawn”, and “Suspended” are defined as class 0.
Those with values “Unknown status” are deleted and not included in the
classification task. In terms of determining the optimal probability
threshold for converting probabilities to classes in prediction, we used
the pROC package that helps determine the optimal threshold.</p>
<div class="sourceCode" id="cb13"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="fu"><a href="../reference/status_classification.html">status_classification</a></span><span class="op">(</span><span class="op">)</span></span>
<span><span class="co">#&gt; Setting levels: control = 0, case = 1</span></span>
<span><span class="co">#&gt; Setting direction: controls &lt; cases</span></span>
<span><span class="co">#&gt;             </span></span>
<span><span class="co">#&gt; pred_results   0   1</span></span>
<span><span class="co">#&gt;            0  63  66</span></span>
<span><span class="co">#&gt;            1  16 287</span></span>
<span><span class="co">#&gt; [1] "Accuracy of Logistic Regression Model: 0.810185185185185"</span></span></code></pre></div>
<p><img src="abstract_files/figure-html/unnamed-chunk-12-1.png" width="700"></p>
</div>
</div>
</div>
<div class="section level2">
<h2 id="interpretation-and-conclusions">Interpretation and Conclusions<a class="anchor" aria-label="anchor" href="#interpretation-and-conclusions"></a>
</h2>
<p>To determine the significant factors influencing enrollment numbers
in mCRC clinical trials, ANOVA tests were conducted. All three ANOVA
summary tables indicate highly significant differences in enrollment
numbers across the different phases of clinical trials, source classes,
and study duration, as evidenced by a very low p-value (&lt;0.05). The
Tukey’s HSD plot presents confidence intervals for pairwise differences
between phases. The plot shows several intervals (phase 3, phase 4,
etc.) that do not include zero, indicating significant differences in
mean enrollment between certain phases. The Kruskal-Wallis rank sum test
result indicates a highly significant difference in enrollment numbers
across various source classes of clinical trials (with chi-squared =
103.3). This suggests that the source class is likely an influential
factor affecting enrollment in these trials.</p>
<p>To predict the collective influence of different factors on the study
duration of mCRC clinical trials, a multivariate linear regression model
was developed. The regression output and diagnostic plots provide
insight into the relationship between study duration and the predictors.
The output shows that enrollment, NIH (as a source class), and the trial
phase have significant effects on study duration. For instance, being
funded by the NIH is associated with an increase in study duration, as
indicated by a large positive coefficient that is statistically
significant. The diagnostic plots suggest that the residuals are
reasonably well-behaved, with no obvious patterns in the Residuals vs
Fitted plot. The Scale-Location plot indicates that the variance of
residuals is relatively constant across the range of fitted values.
Though the Residuals vs Leverage plot identifies a few potential
outliers, they are acceptable as the Cook’s distance for all points is
below the common threshold. The scatter plot of Predicted vs Actual
values shows how well the model’s predictions match the actual data,
with points color-coded by source class. Points falling along the dashed
line represent accurate predictions. The dispersion of points around
this line reflects the variability in prediction accuracy, potentially
due to unaccounted factors affecting study duration. We observed that
the points cluster (or stratified) by source class, revealing that
NIH-sourced trials generally exhibit shorter study durations, suggesting
source-specific influences on trial length.</p>
<p>In order to classify the overall completion status using different
factors, we built a binary logistic regression model with 81.0%
accuracy. This high level of accuracy is evidenced by the confusion
matrix. The model correctly predicted 63 trials as not meeting the
success criteria (true negatives) and 287 as meeting them (true
positives), while misclassifying only 16 as false negatives and 66 as
false positives. The confusion matrix plot visually confirms the model’s
effectiveness, with a clear distinction between successful and
unsuccessful trial classifications.</p>
</div>
<div class="section level2">
<h2 id="discussion">Discussion<a class="anchor" aria-label="anchor" href="#discussion"></a>
</h2>
<p>Potential future directions of the study include carrying out time
series analyses on how the distribution of study phases change over
time, and how other factors such as enrollment number, treatment
approach, and sponsorship come into play. Moreover, to take a step
further, we may conduct meta-analyses on treatment efficacies if outcome
data are available. For example, we can perform survival analyses (e.g.,
Kaplan-Meier curves, log-rank tests) to compare the effectiveness of
different therapeutic drugs.</p>
<p>We also noticed that a large proportion of the studies were
terminated or suspended. While information availabe in the database
could not tell us the exact reasons for termination, it might be
important to investigate factors correlated with trial success such as
trial phase, targeted therapy types, etc.</p>
</div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p></p>
<p>Developed by The package maintainer.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p>
<p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.7.</p>
</div>

    </footer>
</div>

  

  

  </body>
</html>
